Skip to main content
SpringerLink
Log in

Sitafloxacin

DU 6859, DU 6859A, Gracevit™, Sitafloxacin Hydrate

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Aoki H, Tachibana M, Tanaka M, et al. DU-6859a, a novel quinolone: identification of the main metabolite in rats. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 302, 1993

    Google Scholar 

  2. Nakashima M, Uematsu T, Nakano M, Kosuge K, Tanaka M, et al. Pharmacokinetics and safety investigation of a new fluoroquinolone, DU-6859a in healthy male volunteers. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 303, 1993

    Google Scholar 

  3. Spencer L, Oliver S. DU-6859 (sitafloxacin)-absolute bioavailability study in healthy male and female subjects. Clinical Pharmacology and Therapeutics. 69: P48, Feb 2001

    Article  Google Scholar 

  4. Nozaki M, Kohno K, Tsurumi K. No convulsion was observed in mice: concomitant use of DU-6859a and non-steroidal antiinflammatory drugs. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 303, 1993

    Google Scholar 

  5. Kobayashi H. The clinical efficacy of sitafloxacin (DU-6859a) in respiratory tract infection. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 130 (plus poster), Jul 1999

    Google Scholar 

  6. Matsuda S. Clinical efficacy and tissue penetration of sitafloxacin (DI-6859a) in obstetrical and gynaecological infections. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 144 (plus poster), Jul 1999. Koto Hospital, Tokyo, Japan

    Google Scholar 

  7. Sasaki J. Clinical efficacy of sitafloxacin (DU-6859a) against infectious diseases in dentistry and oral surgery, and its pharmacokinetics. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 140–141 (plus poster), Jul 1999

    Google Scholar 

  8. Niki Y, Itokawa K, Okazaki O. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy. 42: 1751–1755, Jul 1998

    PubMed  CAS  Google Scholar 

  9. Ishida Y, Otani T, Ohashi M, Someya K, Yoshida K, et al. DU- 6859a, a new quinolone: therapeutic efficacy on experimental pneumonia due to Pseudomonas aeruginosa and Streptococcus pneumoniae. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 302, 1993

    Google Scholar 

  10. Saito H, Tomioka H, Sato K, Dekio S. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrobial Agents and Chemotherapy. 38: 2877–2882, Dec 1994

    Article  PubMed  CAS  Google Scholar 

  11. Mikamo H, Kawazoe K, Sato Y, Izumi K, Tamaya T. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. Journal of Antimicrobial Chemotherapy 41: 131–133, Jan 1998

    Article  PubMed  CAS  Google Scholar 

  12. Miyashita N, Niki Y, Matsushima T. In vitro and in vivo activities of sitafloxacin against Chlamydia spp. Antimicrobial Agents and Chemotherapy 45: 3270–3272, Nov 2001

    Article  PubMed  CAS  Google Scholar 

  13. Inagaki Y, Yamamoto N, Chida T, Okamura N, Tanaka M. The effect of DU-6859a, a new potent fluoroquinolone, on fecal microflora in human volunteers. Japanese Journal of Antibiotics 48: 368–379, Mar 1995

    PubMed  CAS  Google Scholar 

  14. Marshall SA, Jones RN, Murray PR, Washington JA, Allen SD, et al. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates. Journal of Antimicrobial Chemotherapy 32: 877–884, Dec 1993

    Article  PubMed  CAS  Google Scholar 

  15. Tomayko JF, Korten V, Murray BE. DU-6859a, a new fluoroquinolone agent: comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coli. Diagnostic Microbiology and Infectious Disease 20: 45–47, Sep 1994

    Article  PubMed  CAS  Google Scholar 

  16. Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrobial Agents and Chemotherapy 36: 1491–1498, Jul 1992

    Article  PubMed  CAS  Google Scholar 

  17. Felmingham D, Robbins MJ, Ghosh G, Bhogal H, Mehta M, et al. In vitro studies with DU-6859a — a new fluorochloroquinolone antimicrobial. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 299, 1993

    Google Scholar 

  18. Molitoris E, Wexler HM, Reeves D, Finegold SM. In vitro activity of DU 6859a against 330 strains of anaerobic bacteria. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 301, 1993

    Google Scholar 

  19. Forstall GJ, Knapp CC, Washington JA. Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci. Antimicrobial Agents and Chemotherapy 38: 1868–1870, Aug 1994

    Article  PubMed  CAS  Google Scholar 

  20. Kuwahara-Arai K, Hori S, Hiramatsu K. In vitro antimicrobial activity of a novel quinolone DU-6859a. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 298, 1993

    Google Scholar 

  21. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of DU- 6859A, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. 5th International Symposium on New Quinolones: 44, 1994

    Google Scholar 

  22. Jones RN, Johnson DM, Biedenbach DJ, Marshall SA. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagnostic Microbiology and Infectious Disease 23: 123–127, Nov 1995

    Article  PubMed  CAS  Google Scholar 

  23. Deguchi T, Yasuda M, Nakano M, Kanematsu E, Ozeki S, et al. Antimicrobial activity of a new fluoroquinolone, DU- 6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV. Journal of Antimicrobial Chemotherapy. 39: 247–249, Feb 1997

    Article  PubMed  CAS  Google Scholar 

  24. Goldstein EJC, Citron DM, Hunt Gerardo S, Hudspeth M, Vreni Merriam C. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates. Antimicrobial Agents and Chemotherapy 41: 1193–1195, May 1997

    PubMed  CAS  Google Scholar 

  25. Milatovic D, Fluit A, Schmitz F-J, Verhoef J. In vitro activity of sitafloxacin (DU-6859A) and six other fluoroquinolones. Part III: anaerobes. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 171 (plus poster), Jul 1999

    Google Scholar 

  26. Ackermann G, Tang YJ, Rodloff AC, Silva Jr J, Cohen SH, et al. In vitro activity of sitafloxacin against Clostridium difficile. Journal of Antimicrobial Chemotherapy. 47: 722–724, May 2001

    Article  PubMed  CAS  Google Scholar 

  27. Giamarellos-Bourboulis EJ, Grecka P, Sambatakou H, et al. Comparative postantibiotic effect of sitafloxacin and trovafloxacin on methicillin-resistant Staphylococcus aureus. Drugs 58 (Suppl 2): 146–148, 1999

    Article  CAS  Google Scholar 

  28. Kawada Y. Sitafloxacin (DU-6859a) in the treatment of genitourinary tract infections. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 142 (plus poster), Jul 1999

    Google Scholar 

  29. Watanabe S, Arata J. Use of sitafloxacin (DU-6859a) in the treatment of skin infections and its skin penetration. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 146 (plus poster), Jul 1999

    Google Scholar 

  30. Baba S. Clinical efficacy of sitafloxacin (DU-6859a) in otorhinolaryngological infections and its pharmacokinetics. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 146 (plus poster), Jul 1999

    Google Scholar 

  31. Irimajiri S, Research Group for Infectious Enteric Diseases. Multi-center clinical trial of sitafloxacin (DU-6859a) in infectious enteritis. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 143 (plus poster), Jul 1999

    Google Scholar 

  32. Ooishi M. Clinical efficacy and pharmacokinetics of sitafloxacin (DU-6859a) in the field of ophthalmology. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 144 (plus poster), Jul 1999

    Google Scholar 

  33. Takifuji K, Tanimura H, Nagai Y, Iwakura S. Clinical effects of sitafloxacin (DU-6859a) on surgical infection and pharmacokinetic evaluation. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 146 (plus poster), Jul 1999

    Google Scholar 

  34. Shetty N, Wilson APR. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 46: 633–637, Oct 2000

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sitafloxacin. Drugs in R&D 4, 61–68 (2003). https://doi.org/10.2165/00126839-200304010-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304010-00013

Keywords

Search

Navigation